Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Return on Capital Employed (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Return on Capital Employed readings, the most recent being 3.07% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 877.0% to 3.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.07%, a 877.0% decrease, with the full-year FY2025 number at 3.21%, down 1207.0% from a year prior.
  • Return on Capital Employed hit 3.07% in Q4 2025 for Fennec Pharmaceuticals, up from 12.52% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 16.34% in Q1 2024 to a low of 142.25% in Q2 2023.
  • Median Return on Capital Employed over the past 5 years was 66.54% (2021), compared with a mean of 57.55%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -4970bps in 2022 and later surged 15229bps in 2024.
  • Fennec Pharmaceuticals' Return on Capital Employed stood at 65.32% in 2021, then crashed by -44bps to 93.85% in 2022, then increased by 14bps to 80.48% in 2023, then soared by 107bps to 5.7% in 2024, then tumbled by -154bps to 3.07% in 2025.
  • The last three reported values for Return on Capital Employed were 3.07% (Q4 2025), 12.52% (Q3 2025), and 25.99% (Q2 2025) per Business Quant data.